Fulcrum plummets 50% after scrapping lead sickle-cell drug on FDA concerns

Aggregated and edited by the Scoop newsroom. We surface news from Investing.com alongside other reporting so you can compare coverage in one place. Editorial policy · Corrections · About Scoop